HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer
1 clinical trials · Condition
◉ Watch HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer
| Record | Firm | Date |
|---|---|---|
| A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer (NCT07393321) | Nanjing Chia-tai Tianqing Pharmaceutical | 2026-02-10 |
Track HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.